Company Encyclopedia
View More
name
Eli Lilly
LLY.US
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
4.514 T
LLY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking1/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE96.82%A
    • Profit Margin30.99%A
    • Gross Margin82.91%A
  • Growth ScoreA
    • Revenue YoY45.41%A
    • Net Profit YoY119.98%A
    • Total Assets YoY52.02%A
    • Net Assets YoY66.55%A
  • Cash ScoreB
    • Cash Flow Margin322.72%C
    • OCF YoY45.41%A
  • Operating ScoreB
    • Turnover0.62B
  • Debt ScoreE
    • Gearing Ratio79.25%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dow Jones futures up, Novo Nordisk down. Market recovery needed after recent losses. Nvidia, Apple, Eli Lilly in focus.

    Following significant recent losses, the stock market is in need of a strong rebound. Investors are advised to keep a close eye on Nvidia, Apple, and Eli Lilly. Dow Jones Futures have seen a promising rise, while Novo Nordisk has experienced a significant dip. This update emphasizes the importance of monitoring these key companies for potential shifts in the market.

    Unusual Whales·
    US
    NVDA
    +2.12%
    US
    LLY
    -1.85%
    US
    AAPL
    -1.21%
    Unusual Whales·
    US
    NVDA
    +2.12%
    US
    LLY
    -1.85%
    US
    AAPL
    -1.21%

    Small caps approach all-time highs, Eli Lilly at key level, 5 stocks in buy zones as Dow Jones futures surge. Ulta Beauty posts strong earnings. Robinhood leads new buys.

    Small-cap stocks are nearing all-time highs as Dow Jones futures surge. Eli Lilly's stock is at a critical level, while Ulta Beauty reports strong earnings. Robinhood leads new stock purchases, and five stocks are in buy zones, indicating promising investment opportunities.

    Unusual Whales·
    US
    ULTA
    -1.94%
    US
    LLY
    -1.85%
    Unusual Whales·
    US
    ULTA
    -1.94%
    US
    LLY
    -1.85%

    Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

    Eli Lilly & Co. (LLY) shares fell 1.85% to $1,014.49 on Thursday, marking the sixth consecutive day of losses. The stock underperformed compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. It closed 8.77% below its 52-week high. Trading volume was slightly below the 50-day average. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%.

    Dow Jones·
    US
    LLY
    -1.85%
    Dow Jones·
    US
    LLY
    -1.85%

    What's Up With The Jump In Viking Therapeutics Stock?

    Viking Therapeutics (VKTX) shares rose 11.17% due to excitement in obesity treatment and positive clinical trial developments. The company completed patient enrollment for its Phase 3 VANQUISH-1 trial ahead of schedule, attracting more participants than expected. This momentum is part of a broader interest in GLP-1 and obesity drug developers, with major players like Eli Lilly and Novo Nordisk competing in the market. VKTX shows strong short-term momentum, trading above its 20-day and 200-day SMA, indicating a bullish trend.

    fidelity·
    US
    LLY
    -1.85%
    US
    NVO
    +0.88%
    US
    VKTX
    +8.92%
    fidelity·
    US
    LLY
    -1.85%
    US
    NVO
    +0.88%
    US
    VKTX
    +8.92%

    Top Pharmaceutical Stocks To Add to Your Watchlist - December 4th

    MarketBeat highlights Eli Lilly, Novo Nordisk, and Bristol Myers Squibb as top pharmaceutical stocks to watch. These companies offer exposure to healthcare innovation but carry risks related to clinical trials, regulatory approvals, and sector-specific activities. Despite Eli Lilly's moderate buy rating, analysts suggest other stocks may offer better returns.

    Market Beat·
    US
    BMY
    +1.94%
    US
    NVO
    +0.88%
    US
    LLY
    -1.85%
    Market Beat·
    US
    BMY
    +1.94%
    US
    NVO
    +0.88%
    US
    LLY
    -1.85%
    Posts
    View More

    In today’s pre-mkt summary for Subscribers: Stocks extended declines as doubts over the credit health of regional US banks drove traders to reduce risk. Gold and bonds were major beneficiaries as in...............

    hihingiin ang isa

    Longbridge - Motley Fool
    Motley Fool

    Stevens Capital Closes Out Position in Eli Lilly

    Stevens Capital Management LP has completely exited its position in Eli Lilly, selling all 12,036 shares in Q2 2025 for approximately $9.94 million. Following this sale, the fund's top holdings include Strategy ($35.09 million), CME Group ($20.69 million), and Apple ($19.38 million). Eli Lilly's stock has underperformed the S&P 500 by 38.3 percentage points over the past year, with a total return of -23.1%. The company, valued at $658.15 billion, continues to compete in the weight-loss drug market against Novo Nordisk.

    $Eli Lilly(LLY.US) broke through 723, entering a bull market.

    $Eli Lilly(LLY.US) looks compelling even after rebounding +12% off its lows last week after its Orforglipron weight loss pill showed lower efficacy than expected in Phase 3 trials, sending the stock d...

    ............
    • 0
    • 1
    © 2025 Longbridge｜Disclaimer